دورية أكاديمية
أعرض في EDS

Leftover of Amoxicillin Suspension After Use by Children in the Netherlands.

التفاصيل البيبلوغرافية
العنوان: Leftover of Amoxicillin Suspension After Use by Children in the Netherlands.
المؤلفون: Sadreghaemy M; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Gamba MA; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Egberts TCG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
المصدر: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Aug; Vol. 33 (8), pp. e5868.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic) Linking ISSN: 10538569 NLM ISO Abbreviation: Pharmacoepidemiol Drug Saf Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Chichester, West Sussex : Wiley, 1992-
مواضيع طبية MeSH: Amoxicillin*/administration & dosage , Anti-Bacterial Agents*/administration & dosage , Suspensions*, Humans ; Netherlands ; Child, Preschool ; Infant ; Child ; Retrospective Studies ; Female ; Male ; Infant, Newborn ; Practice Patterns, Physicians'/statistics & numerical data ; Cohort Studies ; Pharmacies/statistics & numerical data ; Drug Prescriptions/statistics & numerical data ; Drug Packaging ; Databases, Factual
مستخلص: Purpose: In clinical practice, a discrepancy may exist between the prescribed amount of a drug and the commercially available pack sizes in the pharmacy, potentially contributing to drug waste. This study aimed-as an example of this phenomena-to quantify leftover of amoxicillin suspension prescribed to children, due to discrepancies between physician-prescribed and pharmacy-dispensed amounts.
Methods: We performed a retrospective cohort study including amoxicillin suspension dispensations for patients aged 0-12 years between 2017 and 2019 utilizing the Dutch PHARMO database. Leftover amount of amoxicillin was estimated by assessing the discrepancy between the prescribed and dispensed amounts. Extrapolated amoxicillin weight and economic spillage estimates for the Netherlands were determined. The impact of two theoretical interventions on leftover amount was assessed: (1) introducing vials with half the volume of the current 100 and 30 mL vials and (2) a combination of the first intervention with a maximum of 10% round-down by the dispensing pharmacy of the prescribed dose.
Results: We included 79 512 amoxicillin suspension dispensations for 62 252 patients. The mean leftover amount of amoxicillin suspension per dispensing was 27%. The yearly amount of amoxicillin leftover was 49.8 kg in the study cohort, equivalent to yearly 633 kg and €621 000 when extrapolated to the Netherlands. Employing the first theoretical intervention reduced the mean leftover per dispensing to 20%, reducing the yearly leftover to 31.6 kg amoxicillin in the study cohort, and to 400 kg and €400 000 extrapolated. The second theoretical intervention further reduced leftover to 17%, reducing the yearly leftover to 24.3 kg amoxicillin in the study cohort, and to 300 kg and €300 000 extrapolated.
Conclusion: Approximately a quarter of amoxicillin suspension remains as leftover per dispensing. Applying different theoretical intervention shows the potential for a significant reduction of amoxicillin leftover.
(© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.)
References: M. Nemcova, J. Pikula, J. Zukal, and V. Seidlova, “Diclofenac‐Induced Cytotoxicity in Cultured Carp Leukocytes,” Physiological Research 69, no. Suppl 4 (2020): S607–S618.
L. Chow, L. Waldron, and M. R. Gillings, “Potential Impacts of Aquatic Pollutants: Sub‐Clinical Antibiotic Concentrations Induce Genome Changes and Promote Antibiotic Resistance,” Frontiers in Microbiology 6 (2015): 803.
K. M. Chong, K. Rajiah, D. Chong, and M. K. Maharajan, “Management of Medicines Wastage, Returned Medicines and Safe Disposal in Malaysian Community Pharmacies: A Qualitative Study,” Frontiers in Medicine (Lausanne) 9 (2022): 884482.
K. Guirguis, “Medications Collected for Disposal by Outreach Pharmacists in Australia,” Pharmacy World & Science 32, no. 1 (2010): 52–58.
C. L. Bekker, E. J. Melis, A. C. G. Egberts, M. L. Bouvy, H. Gardarsdottir, and B. J. F. van den Bemt, “Quantity and Economic Value of Unused Oral Anti‐Cancer and Biological Disease‐Modifying Anti‐Rheumatic Drugs Among Outpatient Pharmacy Patients Who Discontinue Therapy,” Research in Social & Administrative Pharmacy 15, no. 1 (2019): 100–105.
D. D. Maeng, L. A. Tom, and E. A. Wright, “Patient Characteristics and Healthcare Utilization Patterns Associated With Unused Medications Among Medicare Patients,” Research in Social & Administrative Pharmacy 13, no. 6 (2017): 1090–1094.
L. M. West, L. Diack, M. Cordina, and D. Stewart, “A Systematic Review of the Literature on “Medication Wastage”: An Exploration of Causative Factors and Effect of Interventions,” International Journal of Clinical Pharmacy 36, no. 5 (2014): 873–881.
E. M. Smale, B. J. F. van den Bemt, E. R. Heerdink, et al., “Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs: The ROAD Study,” JAMA Oncologia 10 (2023): 87.
B. J. Akhavan, N. R. Khanna, and P. Vijhani, “Amoxicillin,” in StatPearls [Internet] (Treasure Island (FL): StatPearls Publishing, 2022), 387–396, https://www.ncbi.nlm.nih.gov/books/NBK482250/.
C. R. Lee, I. H. Cho, B. C. Jeong, and S. H. Lee, “Strategies to Minimize Antibiotic Resistance,” International Journal of Environmental Research and Public Health 10, no. 9 (2013): 4274–4305.
T. F. Landers, B. Cohen, T. E. Wittum, and E. L. Larson, “A Review of Antibiotic Use in Food Animals: Perspective, Policy, and Potential,” Public Health Reports 127, no. 1 (2012): 4–22.
C. M. Lathers, “Role of Veterinary Medicine in Public Health: Antibiotic Use in Food Animals and Humans and the Effect on Evolution of Antibacterial Resistance,” Journal of Clinical Pharmacology 41, no. 6 (2001): 595–599.
R. Mulchandani, Y. Wang, M. Gilbert, and T. P. V. Boeckel, “Global Trends in Antimicrobial Use in Food‐Producing Animals: 2020 to 2030,” PLOS Global Public Health 3, no. 2 (2023): e0001305.
C. A. M. McNulty, P. Boyle, T. Nichols, P. Clappison, and P. Davey, “The Public's Attitudes to and Compliance With Antibiotics,” Journal of Antimicrobial Chemotherapy 60, no. S1 (2007): i63–i68.
S. I. Polianciuc, A. E. Gurzău, B. Kiss, M. Georgia Ștefan, and F. Loghin, “Antibiotics in the Environment: Causes and Consequences,” Medicine and Pharmacy Reports 93, no. 3 (2020): 231.
Pharmo, “The PHARMO Institute Is an Internationally Recognized Organisation, Dedicated to the Improvement of the Use, Quality and Cost‐Effectiveness of Pharmaceuticals. We Collect, Maintain and Perform Research on Patient‐Centric Data to Derive Real‐Life Insights for Tailoring of Medicines,” 2022, https://pharmo.nl/.
KNMP‐Kennisbank, “G‐Standaard Handelsproducten,” 2022, www.kennisbank.knmp.nl.
“Welkom bij de SFK—SFK Website,” 2023, https://www.sfk.nl/.
P. B. Bach, R. M. Conti, R. J. Muller, G. C. Schnorr, and L. B. Saltz, “Overspending Driven by Oversized Single Dose Vials of Cancer Drugs,” BMJ 29, no. 352 (2016): i788.
J. A. Bielicki, W. Stöhr, S. Barratt, et al., “Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re‐Treatment in Children With Community‐Acquired Pneumonia: The CAP‐IT Randomized Clinical Trial,” Journal of the American Medical Association 326, no. 17 (2021): 1713–1724.
I. I. Andreadis, C. I. Gioumouxouzis, G. K. Eleftheriadis, and D. G. Fatouros, “The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing?” Pharmaceutics 14, no. 3 (2022): 609.
X. Xu, J. Zhao, M. Wang, L. Wang, and J. Yang, “3D Printed Polyvinyl Alcohol Tablets With Multiple Release Profiles,” Scientific Reports 9, no. 1 (2019): 12487.
Y. Thabet, V. Klingmann, and J. Breitkreutz, “Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics,” Journal of Clinical Pharmacology 58, no. S10 (2018): S26–S35.
C. Karavasili, A. Gkaragkounis, and D. G. Fatouros, “Patent Landscape of Pediatric‐Friendly Oral Dosage Forms and Administration Devices,” Expert Opinion on Therapeutic Patents 31, no. 7 (2021): 663–686.
G. P. Giacoia, P. Taylor‐Zapata, and A. Zajicek, “Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: Proceedings From the Second Workshop on Pediatric Formulations,” Clinical Therapeutics 34, no. 11 (2012): S1–S10.
R. Wiedey, M. Kokott, and J. Breitkreutz, “Orodispersible Tablets for Pediatric Drug Delivery: Current Challenges and Recent Advances,” Expert Opinion on Drug Delivery 18, no. 12 (2021): 1873–1890.
R. El Edelbi, S. Eksborg, and S. Lindemalm, “In Situ Coating Makes It Easier for Children to Swallow and Tolerate Tablets and Capsules,” Acta Paediatrica 104, no. 9 (2015): 956–961.
D. A. van Riet‐Nales, J. A. Ferreira, A. F. A. M. Schobben, B. J. de Neef, T. C. G. Egberts, and C. M. A. Rademaker, “Methods of Administering Oral Formulations and Child Acceptability,” International Journal of Pharmaceutics 491, no. 1–2 (2015): 261–267.
D. A. van Riet‐Nales, A. F. A. M. Schobben, T. C. G. Egberts, and C. M. A. Rademaker, “Effects of the Pharmaceutical Technologic Aspects of Oral Pediatric Drugs on Patient‐Related Outcomes: A Systematic Literature Review,” Clinical Therapeutics 32, no. 5 (2010): 924–938.
D. A. van Riet‐Nales, A. F. A. M. Schobben, H. Vromans, T. C. G. Egberts, and C. M. A. Rademaker, “Safe and Effective Pharmacotherapy in Infants and Preschool Children: Importance of Formulation Aspects,” Archives of Disease in Childhood 101, no. 7 (2016): 662–669.
T. M. McGuire, “Does Size Matter? Addressing Pack Size and Antibiotic Duration,” Australian Prescriber 42, no. 1 (2019): 2–3.
T. M. McGuire, J. Smith, and C. Del Mar, “The Match Between Common Antibiotics Packaging and Guidelines for Their Use in Australia,” Australian and New Zealand Journal of Public Health 39, no. 6 (2015): 569–572.
R. Braund, Y. C. Yuen, and J. Jung, “Identification and Quantification of Medication Returned to Otago Pharmacies,” NZFP 34, no. 4 (2007): 258–262.
A. J. Mackridge and J. F. Marriott, “Returned Medicines: Waste or a Wasted Opportunity?” Journal of Public Health (Oxford, England) 29, no. 3 (2007): 258–262.
M. R. Toh and L. Chew, “Turning Waste Medicines to Cost Savings: A Pilot Study on the Feasibility of Medication Recycling as a Solution to Drug Wastage,” Palliative Medicine 31, no. 1 (2017): 35–41.
K. Al‐Siyabi and K. Al‐Riyami, “Value and Types of Medicines Returned by Patients to Sultan Qaboos University Hospital Pharmacy, Oman,” Sultan Qaboos University Medical Journal 7, no. 2 (2007): 109–115.
A. B. E. Ekedahl, “Reasons Why Medicines Are Returned to Swedish Pharmacies Unused,” Pharmacy World & Science 28, no. 6 (2006): 352–358.
A. Coma, P. Modamio, C. F. Lastra, M. L. Bouvy, and E. L. Mariño, “Returned Medicines in Community Pharmacies of Barcelona, Spain,” Pharmacy World & Science 30, no. 3 (2008): 272–277.
J. K. J. K. J. K. T. A. L. Smejkalová, “Wastage of Medicines and Its Financial Impact on the Healthcare System in The Czech Republic,” Ceská a Slovenská Farmacie 67, no. 5–6 (2018): 192–199.
C. Langley, J. Marriott, A. Mackridge, and R. Daniszewski, “An Analysis of Returned Medicines in Primary Care,” Pharmacy World & Science 27, no. 4 (2005): 296–299.
K. E. Arnold, G. Laing, B. J. McMahon, et al., “The Need for One Health Systems‐Thinking Approaches to Understand Multiscale Dissemination of Antimicrobial Resistance,” Lancet Planetary Health 8, no. 2 (2024): e124–e133.
فهرسة مساهمة: Keywords: amoxicillin; drug waste; economic spillage; leftover; sustainable drug use
المشرفين على المادة: 804826J2HU (Amoxicillin)
0 (Anti-Bacterial Agents)
0 (Suspensions)
تواريخ الأحداث: Date Created: 20240802 Date Completed: 20240802 Latest Revision: 20240802
رمز التحديث: 20240802
DOI: 10.1002/pds.5868
PMID: 39092463
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-1557
DOI:10.1002/pds.5868